Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/1997

01-01-1997 | ORIGINAL ARTICLE

Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-γ secretion

Authors: Øystein Bruserud, Laila Mentzoni, Brynjar Foss, Jann Bergheim, Sigbjørn Berentsen, Ingerid Nesthus

Published in: Cancer Immunology, Immunotherapy | Issue 5/1997

Login to get access
Metadata
Title
Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-γ secretion
Authors
Øystein Bruserud
Laila Mentzoni
Brynjar Foss
Jann Bergheim
Sigbjørn Berentsen
Ingerid Nesthus
Publication date
01-01-1997
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/1997
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050334

Other articles of this Issue 5/1997

Cancer Immunology, Immunotherapy 5/1997 Go to the issue

ORIGINAL ARTICLE

Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines

ORIGINAL ARTICLE

Effects of granulocyte-colony-stimulating factor and interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells

ORIGINAL ARTICLE

Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin

ORIGINAL ARTICLE

Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of α CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors

ORIGINAL ARTICLE

Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

ORIGINAL ARTICLE

Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits